|Allopurinol for the treatment of chronic kidney disease: a systematic review
|Fleeman N, Pilkington G, Dundar Y, Dwan K, Boland A, Dickson R, Anijeet H, Kennedy T, Pyatt J
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Fleeman N, Pilkington G, Dundar Y, Dwan K, Boland A, Dickson R, Anijeet H, Kennedy T, Pyatt J. Allopurinol for the treatment of chronic kidney disease: a systematic review. Health Technology Assessment 2014; 18(40): 106
The aim of this systematic review was to address the following research question: does allopurinol reduce
mortality, the progression of chronic kidney disease or cardiovascular risk in people with CKD? Given the
importance of adverse events (AEs) (common and rare), a secondary aim was to consider the evidence
from observational studies describing AEs and quality-of-life data.
We reviewed the available studies to consider whether or not using allopurinol in people with chronic
kidney disease may prevent the worsening of their disease. Our review found that there was limited
evidence that allopurinol slows down the progression of chronic kidney disease or reduces the occurrence
of heart disease. However, this evidence was not convincing as it was derived from studies with small
numbers of patients and similar findings were not reported from more than one study. We did identify
that there are very few serious side effects from taking the treatment. However, we cannot say whether or
not patients with kidney disease taking allopurinol have the same side effects as patients taking the drug
for other conditions such as gout. Therefore, we have concluded that additional research is required,
ideally including a trial with a larger number of people with chronic kidney disease.
Subject indexing assigned by CRD
Allopurinols; Renal Insufficiency, Chronic
Country of organisation
An English language summary is available.
Address for correspondence
NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: firstname.lastname@example.org
Date abstract record published